41 results about "Demethylase" patented technology

The invention discloses application and a method of wheat demethylase TaALKBH23 in regulation and control of drought stress resistance of plants, a coding sequence of the demethylase TaALKBH23 is shown as SEQ ID NO: 1, and an amino acid sequence coded by the demethylase TaALKBH23 is shown as SEQ ID NO: 2. The invention provides demethylase TaALKBH23 and a function and application of a coding gene of the demethylase TaALKBH23 in regulation and control of plant drought resistance, and it is found through construction of a TaALKBH23 wheat genetic transformation material that the gene negatively regulates and controls wheat drought resistance. It is found that TaALKBH23 plays an important role in the process of regulating and controlling drought stress resistance of plants, and a new gene resource is provided for improving drought resistance of crops.

The invention relates to a method for controlling wheat septospora which is resistant to a C14-demethylase inhibitor fungicide. The present invention relates to a method for controlling wheat septospora on a cereal plant, which wheat septospora comprises at least one mutation in the CYP51 gene and is resistant to a C14-demethylase (in sterol biosynthesis) inhibitor fungicide (DMI fungicide), the method comprises applying to these plants, seeds or soil of the plants a fungicidally effective amount of (I) methyl 2-[2-chloro-4-(4-chlorophenoxy) phenyl]-2-hydroxy-3-(1, 2, 4-triazol-1-yl) propionate or (II) 2-[2-chloro-4-(4-chlorophenoxy) phenyl]-2-hydroxy-3-(1, 2, 4-triazol-1-yl) propionic acid.

This invention relates to the application of ALKBH5 as a target in the preparation of drugs for inhibiting the progression of TNBC, and to the drugs themselves. This application discovers mRNA m 6 The alpha-modifying demethylase ALKBH5 is specifically highly expressed in triple-negative breast cancer (TNC). Using spontaneous TNC models and xenograft tumor models, knockout or knockdown of ALKBH5 significantly inhibited breast hyperplasia and the development of TNC, and promoted tumor differentiation. Simultaneously, the specific inhibitor EN300-14040 of ALKBH5 significantly inhibited the growth of TNC organoids, promoted TNC cell differentiation, and enhanced the sensitivity of TNC organoids to the endocrine drug 4OH-T, exhibiting a synergistic inhibitory effect with 4OH-T. Therefore, ALKBH5 represents a potential novel therapeutic target for TNC, and ALKBH5 inhibitors are a potential new type of drug for the treatment of TNC.

The present disclosure is concerned with substituted cyclopropyl carbamate and cyclopropyl sulfonamide compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of various cancers such as, for example, cancers comprising cells that express at least one Sox 2 stem cell marker. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a transgenic plant having increased biomass, yield, and / or abiotic stress tolerance. In particular, the present invention relates to a transgenic plant or plant cell into which a nucleic acid molecule encoding an RNA demethylase FTO (fat mass associated with obesity) protein is introduced. The present disclosure also provides methods of producing plants having increased biomass, yield, and / or abiotic stress tolerance.

This invention belongs to the field of gene editing and epigenetics technology, and discloses a method based on dCasRx-FTO for m 6 A. Editing system and its recombinant expression plasmid, cell model and its application; this invention first constructs an m based on dCasRx-FTO. 6 The A-editing system, namely the dCasRx-FTO fusion protein, utilizes catalytically inactivated CasRx (dCasRx) as a highly specific RNA guidance scaffold to fuse with m 6 A demethylase FTO enables the targeting of a specific region m 6 Targeted removal of A-modification. Building upon this, the present invention further obtains monoclonal mouse embryonic stem cells (mESCs) stably expressing the dCasRx-FTO fusion protein. Combined with an sgRNA library targeting a specific set of transcripts, high-throughput screening can be performed on embryonic stem cells containing the 2C-like pluripotency reporter gene MERVL::tdTomato, thereby identifying key m-modification inhibitors suppressing the pluripotency state of mESCs at the transcriptome level. 6 A modification site, thus enabling its use to reveal m 6 The key role of A-modified targets in the regulation of stem cell pluripotency.

The present disclosure relates to mutant enzymes and bacterial strains constructed to produce paraxanthine and 7-methylxanthine from caffeine and methods for the manufacture and use thereof.

The present invention is directed to a transgenic plant and a method for producing the same. In particular, the present invention is directed to a transgenic plant or a plant cell in which a nucleic acid molecule encoding an m6A demethylase is introduced, wherein said m6A demethylase has the following two domains: i) N-terminal domain (NTD) having the function of AlkB oxidation demethylase; and ii) C-terminal domain (CTD). The present invention is also directed to a method for producing said plant, comprising introducing a nucleic acid molecule encoding an m6A demethylase into a regenarable plant cell, and regenerating a transgenic plant from the regenerable plant cell.

Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in tobacco plants and plant parts thereof are provided. The compositions comprise isolated polynucleotides and polypeptides for a root-specific nicotine demethylases, CYP82E10, and variants thereof, that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Compositions of the invention also include tobacco plants, or plant parts thereof, comprising a mutation in a gene encoding a CYP82E10 nicotine demethylase, wherein the mutation results in reduced expression or function of the CYP82E10 nicotine demethylase. Seed of these tobacco plants, or progeny thereof, and tobacco products prepared from the tobacco plants of the invention, or from plant parts or progeny thereof, are also provided. Methods for reducing the level of nornicotine, or reducing the rate of conversion of nicotine to nornicotine, in a tobacco plant, or plant part thereof are also provided. The methods comprise introducing into the genome of a tobacco plant a mutation within at least one allele of each of at least three nicotine demethylase genes, wherein the mutation reduces expression of the nicotine demethylase gene, and wherein a first of these nicotine demethylase genes encodes a root-specific nicotine demethylase involved in the metabolic conversion of nicotine to nornicotine in a tobacco plant or a plant part thereof. The methods find use in the production of tobacco products that have reduced levels of nornicotine and its carcinogenic metabolite, NNN, and thus reduced carcinogenic potential for individuals consuming these tobacco products or exposed to secondary smoke derived from these products.

To provide a production method of lysine-specific demethylase (LSD1) inhibitors that is easier to implement and has higher yields.SOLUTION: A method for producing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof comprises the step of converting a compound C to a compound D in a solvent under the action of an oxidizing agent.SELECTED DRAWING: None

Provided herein are engineered pyocyanin demethylases having replacements in in positions A53, I73, A87, T91, M99, A129 and K141 of pyocyanin demethylase PodA of SEQ ID NO: 1 or a derivative thereof and related phenazine degrading agents, compositions, methods and systems, as well as a combined administration of one or more pyocyanin demethylases and antibiotics and / or antibiotics resulting in a synergic inhibition of viability of phenazine producing bacteria, and related phenazine degrading agents, compositions, methods and systems.

A method of decreasing conversion of nicotine to nornicotine is provided herein. The methods includes administering at least one basic region / leucine zipper (bZIP) type transcription factor inhibitor to an organism in need thereof. Also provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a bZIP type transcription factor binding site on a promoter of a nicotine N-demethylase (NND). Further provided herein is a method of decreasing conversion of nicotine to nornicotine including mutating a plant genome to knockout at least one bZIP type transcription factor.

This invention discloses a compound seed treatment agent containing metalaxyl-M and tebuconazole, its preparation method, and its uses, belonging to the technical field of seed treatment agents. The suspension of this invention uses metalaxyl-M, tebuconazole, and sodium selenite as the main components, supplemented with emulsifying and dispersing agents, wetting and dispersing agents, antifreeze agents, suspending agents, film-forming agents, and warning colors, and is prepared by adding deionized water to a sufficient volume. Metalaxyl-M targets and inhibits ribosomal RNA polymerase I of oomycete pathogens, while tebuconazole targets and inhibits sterol 14α-demethylase. The two have complementary fungicidal spectra, synergistically controlling maize stalk rot and maize head smut. Sodium selenite, by inhibiting the oxidative stress defense system of pathogenic fungi involving glutathione and thioredoxin, promotes the effects of the two main components and simultaneously remediates selenium-deficient soils. This invention is suitable for the green and efficient control of maize stalk rot and head smut, and also has the function of ecological restoration of selenium-deficient soils.

The invention discloses a GLP-1-based FTO adjustment experiment device, which comprises two pieces of I-shaped steel, the upper ends of the two pieces of I-shaped steel are fixedly provided with a first fixing frame, a second fixing frame and a third fixing frame at equal intervals, and the first fixing frame is provided with a filter box; the method for adjusting the FTO experimental device based on the GLP-1 comprises the following steps: selecting 6-8-week-old mice, feeding the mice with high-fat diet for 12 weeks, establishing an atherosclerosis model, obtaining required animal tissues after the mice are killed, and carrying out subsequent experiments. The specific mechanism that GLP-1 regulates demethylase FTO to change the m6A methylation level of a differential gene so as to delay the atherosclerosis progress is deeply explored, an epigenetic regulation mechanism in the occurrence and development process of cardiovascular diseases is revealed, and a new theoretical basis is provided for research of the cardiovascular diseases; the field and thought of cardiovascular disease research are expanded, a new theoretical basis is provided for prevention and treatment of cardiovascular diseases, and the morbidity and mortality of the cardiovascular diseases can be reduced.

An m 6 A demethylase gene, named AhALKBH15 gene, the RNA sequence of which is shown as SEQ ID NO: 1, and the amino acid sequence encoded by the AhALKBH15 gene is shown as SEQ ID NO: 2. An anti-Ralstonia solanacearum resistance gene AhCQ2G6Y, the RNA sequence of which is shown as SEQ ID NO: 3. The amino acid sequence of the AhCQ2G6Y gene is shown as SEQ ID NO: 4. The m 6 A demethylase AhALKBH15 can remove the m 6 A modification, resulting in m 6 A level is reduced, the resistance gene AhCQ2G6Y is up-regulated, and the up-regulation of AhCQ2G6Y expression promotes the resistance of peanuts to BW. The great potential of AhALKBH15 for peanut resistance breeding is found.

The present application relates to a kind of molecular marker for diagnosing cancer, kit and its application, belong to biotechnology field.The present application provides the m 6 A modification as a molecular marker for diagnosing cancer, the m 6 A modification site is A923, A930 and A955, 3 m 6 A modification site is regulated by demethylase FTO and ALKBH5, promotes HRAS protein expression and the proliferation and metastasis of cancer cell.The present application first identifies the epigenetic transcription modification of HRAS and clarifies relevant molecular mechanism, provides new single / combination targeting treatment theoretical basis for RAS this "difficult drug target".

The application discloses a m6A demethylase-regulated radish bolting and flowering gene RsSUF4 and application thereof, relates to the field of bioengineering technology, and has the technical points that the gene is RsSUF4. The functions of the demethylase RsALKBH10B and the inhibited flowering gene RsSUF4 gene in the flowering process are analyzed, and the specific correlation mechanism between m6A modification and radish flowering regulation is determined.

The invention discloses optimization of a Cas12i3-5M-based soybean efficient multi-gene editing system and application of the Cas12i3-5M-based soybean efficient multi-gene editing system in creation of high-oleic-acid beany-smell-free germplasm resources. The system comprises a basic gene editing vector pSoC12i-V0, a promoter in a nuclease expression module is replaced by a soybean endogenous strong expression promoter GmM4pro, a human demethylase gene hsFTO synergistic module driven by GmM8pro is introduced, a tRNA processing ribozyme RNase P is adopted in a crRNA expression module for optimization, and the gene editing vector pSoC12i-V3 is constructed. The system can be used for efficiently and synchronously editing a plurality of target genes. A soybean variety 'Dongshen-89' is taken as a receptor, crRNA is designed for five genes of GmLOX1, GmLOX2, GmLOX3, GmFAD2-1A and GmFAD2-1B, and a new germplasm with high oleic acid content and no beany flavor, which is homozygically mutated at five targets, is successfully created. The invention provides an efficient gene editing tool and a new germplasm resource for soybean directional breeding and character polymerization.

The invention discloses a method for efficiently screening a functional enzyme and application of the functional enzyme, a demethylase is rapidly screened through matrix-assisted laser desorption / ionization mass spectrometry (MALDI-MSI) combined with non-targeted metabonomics and transcriptomics analysis, and the demethylase can be converted into dihydroberberine by taking palmatine as a substrate, so that the functional enzyme can be efficiently screened. And the enzyme mining efficiency and accuracy are obviously improved. The functional enzyme mining strategy provided by the invention solves the problem that more comprehensive information of natural metabolites and functional enzymes cannot be obtained by a traditional method, and is more beneficial to environmental protection and sustainable development.

The present application provides a method for regulating the activity of functional nucleic acid, which comprises modifying one or more bases of the functional nucleic acid to inactivate the functional nucleic acid. Preferably, the functional nucleic acid or the substrate of the functional nucleic acid is modified to inactivate the functional nucleic acid, and then the modified group is removed to activate the functional nucleic acid. The present application also provides a deoxyribozyme molecular probe, which comprises domain a, domain b and domain c. The deoxyribozyme molecular probe is obtained by screening 6 A closed Dz, which realizes m 6 A high-efficiency and sensitive detection of demethylase and screening and detection of inhibitor small molecule drugs.

The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and / or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and / or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and / or Suv39h2.

The invention relates to a transgenic plant cell and a method for producing a transgenic plant. Specifically, the present invention relates to a transgenic plant cell which incorporates a nucleic acid molecule encoding an m6A demethylase (FTO protein) having two domains: an N-terminal domain (NTD) and a C-terminal domain (CTD) of AlkB oxidation demethylase function. The invention also relates to a method of producing a transgenic plant comprising introducing a gene encoding said m6A demethylase into a renewable plant cell, and regenerating the transgenic plant from said renewable plant cell.

The application provides modified immune effector cells wherein a Lysine Demethylase 4A (KDM4A) gene or gene product is modified in the cell so that the expression and / or function of KDM4A in the cell is reduced or eliminated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

The invention relates to the technical field of stem cell engineering and anti-aging biology, in particular to a histone modification regulation method based on placenta amnion sub-totipotent stem cells and an anti-aging preparation thereof. The regulation and control method comprises the following steps: separating and purifying healthy full-month caesarean section placenta amniotic membrane tissues, carrying out composite enzymolysis and flow cytometry screening to obtain CD105 < + >, CD73 < + > and CD45 <-> stem cells, and primarily culturing the CD105 < + >, CD73 < + > and CD45 <-> stem cells; the method comprises the following steps: determining histone methyltransferase MLL3 and demethylase JMJD3 as target spots through ChIP-seq, and determining H3K4me3 and H3K27me3 as target modification sites; an MLL3 activator CM-272 with the final concentration of 15 [mu] M and a JMJD3 inhibitor GSK-J4 with the final concentration of 10 [mu] M form a composite regulator, and induction culture is performed for 84 h under the conditions of 37 DEG C and 5% CO2; and carrying out Western Blot verification and screening on the stem cells meeting the standard. According to the anti-aging preparation, regulated stem cells are used as active ingredients, a sodium alginate-gelatin (2: 1) composite carrier, 5% mannitol and 1% human serum albumin protective agent are used as auxiliary materials, and the injection with the pH of 7.2-7.4 is prepared. The method is accurate in regulation and control, and the preparation is remarkable in anti-aging effect and low in immunological rejection risk.

Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2 / CCL2 activity, are provided.

The application discloses a kind of m6A demethylase ALKBH1 small molecule inhibitor, synthesis method and application, it is related to pharmaceutical technical field, the m6A demethylase ALKBH1 small molecule inhibitor has the chemical structural formula described in formula (I).The m6A demethylase ALKBH1 small molecule inhibitor of the application has biological activity, can be dose-dependent with ALKBH1 protein in vitro Binding, reduces ALKBH1 enzyme activity, has nanomolar level inhibitory activity, while the effect of the small molecule inhibitor to lung cancer cell A549 is verified, for subsequent screening by computer simulation, precise synthesis m6A demethylase ALKBH1 small molecule inhibitor and application in the disease caused by ALKBH1 overexpression provides broad application prospect.

The present invention relates to a therapeutic agent for use in treating diseases associated with gain of function of the androgen receptor (AR) and / or overexpression of an AR-activating cofactor, such as Kennedy's disease or cancer. The therapeutic agent of the present invention comprises at least one inhibitor of an androgen receptor (AR)-activating cofactor, selected from a protein arginine methyltransferase 6 (PRMT6) inhibitor, a lysine-specific demethylase 1 (LSD1) inhibitor, or a combination thereof.

The application discloses a molecular structure, a long G-quadruplex DNAzyme chain and a supramolecular NMM-G-quadruplex structure. The application further discloses a kit containing DNA1, DNA2 and a circular template. The application further discloses application of the molecular structure, the long G-quadruplex DNAzyme chain, the supramolecular NMM-G-quadruplex structure or the kit in detection of FTO and / or activity of a subfamily thereof. The application further discloses a method for detecting content / activity of FTO and / or a subfamily thereof. The application can accurately recognize and cut demethylated dsDNA, effectively eliminate background signals and improve detection specificity; can realize label-free and sensitive detection of FTO, and the detection limit is as low as 3.10*10 ‑16 M; and has wide application prospects in RNA demethylase related biomedical research and clinical diagnosis.

The application discloses a demethylase ODM gene for synthesizing benzyl isoquinoline alkaloids and application thereof, and the demethylase ODM gene is an ODM4 gene or an ODM5 gene, the CDS region nucleotide sequence of the ODM4 gene is shown as SEQ ID NO:1, and the CDS region nucleotide sequence of the ODM5 gene is shown as SEQ ID NO:2. In view of the fact that the research foundation for key genes for synthesizing corydaline in Corydalis tuber is weak, the ODM4 gene for catalyzing the demethylation of tetrahydropalmatine to specifically generate corydaline and tetrahydrojatrorrhizine and the ODM5 gene for specifically generating tetrahydrojatrorrhizine are cloned from the Corydalis tuber for the first time. The application provides an important theoretical basis for producing corydaline by using a synthetic biology method in the future, and has wide application prospect and great economic value.

Provided herein are engineered pyocyanin demethylases having replacements in in positions A53, 173, A87, T91, M99, A129 and K141 of pyocyanin demethylase PodA of SEQ ID NO: 1 or a derivative thereof and related phenazine degrading agents, compositions, methods and systems, as well as a combined administration of one or more pyocyanin demethylases and antibiotics and / or antibiotics resulting in a synergic inhibition of viability of phenazine producing bacteria, and related phenazine degrading agents, compositions, methods and systems.